purine ribonucleoside triphosphate binding
Definition
Target type: molecularfunction
Binding to a purine ribonucleoside triphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with triphosphate on the sugar. [GOC:BHF, GOC:ebc, ISBN:0198506732]
Purine ribonucleoside triphosphate (pNPT) binding is a critical molecular function involved in numerous cellular processes. It refers to the interaction of a protein or enzyme with purine-based nucleotides, specifically those in their triphosphate form, such as ATP, GTP, CTP, and UTP. These nucleotides serve as essential energy carriers, signaling molecules, and building blocks for nucleic acid synthesis.
The interaction between a protein and pNPT occurs within a specific binding site on the protein. This site typically exhibits a high degree of specificity for purine nucleotides, ensuring that only the correct molecule binds and participates in the biological reaction. The binding event is often facilitated by electrostatic interactions, hydrogen bonds, and van der Waals forces between the nucleotide and the protein's amino acid residues.
The binding of pNPT to a protein can have various consequences depending on the specific protein and its function. Some proteins utilize pNPT as an energy source to drive chemical reactions, such as ATPases that hydrolyze ATP to release energy. Other proteins use pNPT as a signaling molecule, triggering specific cellular responses upon binding. For example, GTPases are involved in signal transduction pathways, where the binding of GTP activates the protein and allows it to interact with downstream targets.
Furthermore, pNPT binding is crucial for nucleic acid synthesis. DNA and RNA polymerases use pNPT molecules as building blocks to elongate nucleic acid chains. In this process, the pNPT molecule is incorporated into the growing nucleic acid strand, while the triphosphate group is cleaved off.
In conclusion, purine ribonucleoside triphosphate binding is a fundamental molecular function with diverse roles in cellular processes. It provides energy, facilitates signaling events, and serves as a building block for nucleic acid synthesis. Understanding this interaction is crucial for comprehending various cellular mechanisms and developing therapeutic strategies for related diseases.'
"
Proteins (1)
| Protein | Definition | Taxonomy |
|---|---|---|
| Proteasome subunit alpha type-6 | A proteasome subunit alpha type-6 that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compounds (18)
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| chlorpromazine | chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety. Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | organochlorine compound; phenothiazines; tertiary amine | anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug |
| clomipramine | clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias. Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. | dibenzoazepine | anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor |
| methixene | methixene: RN given refers to parent cpd; structure | piperidines; thioxanthenes | antiparkinson drug; histamine antagonist; muscarinic antagonist |
| thioridazine | thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position. Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA. | phenothiazines; piperidines | alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist |
| triflupromazine | triflupromazine : A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position. Triflupromazine: A phenothiazine used as an antipsychotic agent and as an antiemetic. | organofluorine compound; phenothiazines; tertiary amine | anticoronaviral agent; antiemetic; dopaminergic antagonist; first generation antipsychotic |
| bortezomib | amino acid amide; L-phenylalanine derivative; pyrazines | antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor | |
| sdz 283-910 | SDZ 283-910: structure in first source | ||
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative. | amino aldehyde; carbamate ester; tripeptide | proteasome inhibitor |
| benzyloxycarbonyl-phe-ala-fluormethylketone | cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1). | ||
| am 404 | anilide | ||
| lactacystin | lactam; S-substituted L-cysteine | ||
| clasto-lactacystin beta-lactone | clasto-lactacystin beta-lactone: active metabolite of lactacystin; inhibits 20 S proteasome; structure in first source | ||
| marizomib | marizomib: a proteasome inhibitor from a marine bacterium Salinospora; structure in first source | beta-lactone; gamma-lactam; organic heterobicyclic compound; organochlorine compound; salinosporamide | antineoplastic agent; proteasome inhibitor |
| carfilzomib | epoxide; morpholines; tetrapeptide | antineoplastic agent; proteasome inhibitor | |
| tyropeptin a | tyropeptin A: proteasome inhibitors produced by Kitasatospora sp. MK993-dF2; structure in first source | dipeptide | |
| belactosin a | belactosin A: isolated from Streptomyces; structure in first source | ||
| oprozomib | ONX 0912: antineoplastic; an orally active proteasome inhibitor; structure in first source | ||
| ixazomib | ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source | benzamides; boronic acids; dichlorobenzene; glycine derivative | antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor |